Prevduo is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2038. Details of Prevduo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11110054 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | Active |
| US11938217 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | Active |
| US10456354 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prevduo's patents.
Latest Legal Activities on Prevduo's Patents
Given below is the list of recent legal activities going on the following patents of Prevduo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
| Email Notification Critical | 26 Mar, 2024 | US11938217 |
| Recordation of Patent Grant Mailed Critical | 26 Mar, 2024 | US11938217 |
| Patent Issue Date Used in PTA Calculation Critical | 26 Mar, 2024 | US11938217 |
| Recordation of Patent eGrant | 26 Mar, 2024 | US11938217 |
| Mail Patent eGrant Notification | 26 Mar, 2024 | US11938217 |
| Email Notification Critical | 07 Mar, 2024 | US11938217 |
| Issue Notification Mailed Critical | 06 Mar, 2024 | US11938217 |
| Dispatch to FDC | 26 Feb, 2024 | US11938217 |
| Application Is Considered Ready for Issue Critical | 26 Feb, 2024 | US11938217 |
US patents provide insights into the exclusivity only within the United States, but Prevduo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prevduo's family patents as well as insights into ongoing legal events on those patents.
Prevduo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Prevduo's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 25, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prevduo Generics:
There are no approved generic versions for Prevduo as of now.
About Prevduo
Prevduo is a drug owned by Azurity Pharmaceuticals Inc. Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as an active ingredient. Prevduo was launched by Azurity in 2023.
Approval Date:
Prevduo was approved by FDA for market use on 23 February, 2023.
Active Ingredient:
Prevduo uses Glycopyrrolate; Neostigmine Methylsulfate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate; Neostigmine Methylsulfate ingredient
Dosage:
Prevduo is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) | SOLUTION | Prescription | INTRAVENOUS |